CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
indacaterol maleate / mometasone furoate +1 moredrug
Likely dose
indacaterol maleate / mometasone furoate 400 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00605306
NCT00605306Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Tolerability of 14-days Treatment With an Inhaled Dose of QMF149 (500/800) in Mild to Moderate Asthmatic Patients

Novartis·interventional·Posted Jan 31, 2008·Updated Apr 22, 2013

In Brief

A Phase 2 clinical trial evaluating indacaterol maleate / mometasone furoate and placebo to indacaterol maleate/mometasone furoate for Asthma. Completed, enrolled 28 participants across 3 sites.

Detailed Summary

This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesFrance
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2008
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.4 years ago

Interventions

indacaterol maleate / mometasone furoatedrug

Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.

placebo to indacaterol maleate/mometasone furoatedrug

Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.